Te Ahumairangi Investment Management Ltd Decreases Stock Position in Roivant Sciences Ltd. $ROIV

Te Ahumairangi Investment Management Ltd cut its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 33.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 108,407 shares of the company’s stock after selling 54,800 shares during the quarter. Te Ahumairangi Investment Management Ltd’s holdings in Roivant Sciences were worth $2,352,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in ROIV. Goldman Sachs Group Inc. boosted its stake in shares of Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after purchasing an additional 324,764 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Roivant Sciences by 1.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after purchasing an additional 34,341 shares during the last quarter. American Century Companies Inc. increased its holdings in Roivant Sciences by 1.9% during the 2nd quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock worth $1,010,000 after purchasing an additional 1,689 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Roivant Sciences by 149.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock worth $129,000 after purchasing an additional 6,879 shares during the last quarter. Finally, M&T Bank Corp increased its holdings in Roivant Sciences by 10.2% during the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock worth $144,000 after purchasing an additional 1,181 shares during the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ROIV shares. TD Cowen lifted their price objective on Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Citigroup lifted their price objective on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. HC Wainwright restated a “buy” rating and set a $34.00 price objective on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, Guggenheim increased their price target on shares of Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $33.59.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $30.27, for a total transaction of $6,054,000.00. Following the completion of the sale, the chief executive officer owned 1,613,063 shares in the company, valued at $48,827,417.01. The trade was a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Matthew Gline sold 289,774 shares of the business’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $29.16, for a total transaction of $8,449,809.84. Following the sale, the chief executive officer owned 16,736,116 shares of the company’s stock, valued at approximately $488,025,142.56. The trade was a 1.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 945,173 shares of company stock worth $27,654,456 in the last ninety days. 10.80% of the stock is currently owned by company insiders.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $29.73 on Friday. Roivant Sciences Ltd. has a one year low of $10.70 and a one year high of $32.79. The company’s 50-day simple moving average is $28.91 and its 200-day simple moving average is $25.95. The stock has a market capitalization of $21.38 billion, a price-to-earnings ratio of -49.55 and a beta of 1.13.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.57. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. The firm had revenue of $2.52 million during the quarter, compared to analyst estimates of $3.41 million. During the same quarter in the previous year, the firm earned ($0.29) earnings per share. As a group, research analysts forecast that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.